Skip to content

ILD-SARDs Registry and Biorepository

Systemic Lupus Erythematosus | Systemic Sclerosis | Rheumatic Diseases | Interstitial Lung...

A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs.

The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Must be aged 18 years or older
2. Diagnosis of ILD as confirmed by a chest CT
3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD
4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures.

Exclusion Criteria:

N/A

Study Location

RI-MUHC
RI-MUHC
Montréal, Quebec
Canada

Contact Study Team

Backup Contact

Victoria Nam-Amnath, RN, BScN

[email protected]
514-934-1934
Primary Contact

Deborah Assayag, MD, MAS

[email protected]
514-934-1934
Study Sponsored By
McGill University Health Centre/Research Institute of the McGill University Health Centre
Participants Required
More Information
Study ID: NCT05007340